Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 9;10(3):1733-1756.
doi: 10.1039/c9ra08706k. eCollection 2020 Jan 7.

SGLT inhibitors as antidiabetic agents: a comprehensive review

Rahul P Kshirsagar  1 , Abhishek A Kulkarni  2 , Rashmi S Chouthe  3 , Shahebaaz K Pathan  2 , Hemant D Une  2 , G Bhanuprakash Reddy  4 , Prakash V Diwan  5 , Siddique Akber Ansari  6 , Jaiprakash N Sangshetti  2
Affiliations
Review

SGLT inhibitors as antidiabetic agents: a comprehensive review

Rahul P Kshirsagar et al. RSC Adv. .

Abstract

Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden. As a metabolic disorder, diabetes is associated with various medical conditions and diseases such as obesity, hypertension, cardiovascular diseases, and atherosclerosis. In this review, we cover the scientific studies on sodium/glucose cotransporter (SGLT) inhibitors published during the last decade. Our focus on providing an exhaustive overview of SGLT inhibitors enabled us to present their chemical classification for the first time.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1. Crystal structure of the SGLT protein.
Fig. 2
Fig. 2. Chemical classification of SGLT1/SGLT2 inhibitors.
None
Rahul P. Kshirsagar
None
Abhishek A. Kulkarni
None
Rashmi S. Chouthe
None
Hemant D. Une
None
Jaiprakash N. Sangshetti
See this image and copyright information in PMC

References

    1. Leung M. Y. M. Pollack L. M. Colditz G. A. Chang S. H. Diabetes Care. 2015;38:460–468. doi: 10.2337/dc14-1453. - DOI - PMC - PubMed
    2. Whiting D. R. Guariguata L. Weil C. Shaw J. E. Diabetes Res. Clin. Pract. 2011;94:311–321. doi: 10.1016/j.diabres.2011.10.029. - DOI - PubMed
    1. Guariguata L. Whiting D. R. Hambleton I. Beagley J. Linnenkamp U. Shaw J. E. Diabetes Res. Clin. Pract. 2014;103:137–149. doi: 10.1016/j.diabres.2013.11.002. - DOI - PubMed
    1. Inzucchi S. E. Bergenstal R. M. Buse J. B. Diamant M. Ferrannini E. Nauck M. Peters A. L. Tsapas A. Wender R. Matthews D. R. Diabetes Care. 2012;35:1364–1379. doi: 10.2337/dc12-0413. - DOI - PMC - PubMed
    2. Groop L. C. Ferrannini E. Bailliere. Clin. Endocrinol. Metab. 1993;7:1007–1032. doi: 10.1016/S0950-351X(05)80243-5. - DOI - PubMed
    1. Turner R. C. Cull C. A. Frighi V. Holman R. R. J. Am. Med. Assoc. 1999;281:2005–2012. doi: 10.1001/jama.281.21.2005. - DOI - PubMed
    1. Nathan D. M. Buse J. B. Davidson M. B. Ferrannini E. Holman R. R. Sherwin R. Zinman B. Diabetes Care. 2009;32:193–203. doi: 10.2337/dc08-9025. - DOI - PMC - PubMed